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The nuclear factor (NF)-B transcription
factor regulates expression of numerous
components of the immune system (Li
and Verma, 2002). These include pro-
inflammatory cytokines, chemokines,
adhesion molecules and inducible
enzymes such as cycloxygenase-2 and
inducible nitric oxide synthase, which
regulate the innate immune response, as
well as proteins that regulate the specific
immune response, such as major
histocompatibility complex and co-
stimulatory molecules crucial to the
induction phase of specific immunity,
and cytokines like interleukin (IL)-2, IL-
12 and interferon- that control
lymphocyte proliferation and
differentiation. Dysregulation of this
transcription factor can thus lead to
inflammatory and autoimmune diseases
(Yamamoto and Gaynor, 2001). Since
NF-B also regulates the expression of a
variety of proteins that inhibit apoptosis
and promote cell survival/proliferation,
it is also implicated in carcinogenesis
(Karin et al., 2002).
NF-B describes various dimeric
complexes of members of the Rel
protein family, which comprises Rel (c-
Rel), Rel A (p65), RelB, NF-B1 (p50
and its precursor p105) and NF-B2
(p52 and its precursor p100) (Ghosh et
al., 1998). Each possesses an ~300-
residue N-terminal Rel-homology-
domain, responsible for dimerisation,
nuclear translocation and DNA binding.
p65, RelB and c-Rel, also contain a C-
terminal transactivation domain. Of the
various dimeric combinations, p50-p65
is most common. Binding of most NF-
B complexes to motifs in target
promoters assists transcription, but
homodimeric complexes of p50 or p52
can repress it.
In resting cells, NF-B proteins are
predominantly cytoplasmic, associating
with members of the inhibitory IB
family such as IB-, IB- and IB-
(Ghosh et al., 1998). These interact with
NF-B through multiple ankyrin repeats
and also inhibit its DNA-binding
activity. IB proteins were originally
thought to sequester NF-B in the
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cytoplasm by masking its nuclear
localisation sequences (NLSs).
However, IB- (and probably IB-)
can only mask one NLS in the dimer; so
NF-B-IB complexes undergo
constitutive nuclear translocation
(Malek et al., 2001). Importantly, a
nuclear export signal (NES) in IB-
precludes high steady-state levels of
these complexes in the nucleus (Huang
et al., 2000). By contrast, NF-B–IB
complexes fail to undergo such shuttling
because IB can mask both NLSs
(Malek et al., 2001). This depends on its
association with the Ras-like protein,
B-Ras (Chen et al., 2003). B-Ras also
increases the stability of IB
(Kanayama et al., 2004).
NF-B complexes containing the
precursor proteins p105 and p100 self-
inactivate (Ghosh et al., 1998).
Interestingly, other IB members can
form part of active transcriptional
complexes at specific promoters. Thus
NF-B-inducible IB (also known as
MAIL and INAP) interacts with p50 and
promotes transcription at the IL-6
promoter (Yamamoto et al., 2004). A
highly related protein, Bcl-3, interacts
with p50 and p52 dimers and forms
active transcriptional complexes (Bours
et al., 1993; Dechend et al., 1999).
However, some studies show it represses
transcription (Richard et al., 1999;
Wessells et al., 2004).
Activation of NF-B classically depends
on degradation of IB. A pre-requisite is
prior phosphorylation of IB on two key
N-terminal serines by IB kinases
(IKKs) (Yamamoto and Gaynor, 2004).
IKK activity resides in a large protein
complex comprising two catalytic
subunits, IKK and IKK, and a
scaffolding subunit, IKK/NEMO. The
phosphorylation of IB proteins is
followed by the binding of the E3IB
ubiquitin ligase complex -TrCP-SCF,
which polyubiquitinylates IB and
targets it for degradation by the 26S
proteasome (Karin and Ben-Neriah,
2000). Activators of the IKK complex
include mitogen-activated protein kinase
kinase kinases (MAP3Ks) such as
MEKK1, MEKK3 and TAK1 and it
represents a convergence point for
numerous stimuli, including ligands for
Toll-like receptors (TLRs), IL-1/IL-18
receptors, the TNF receptor superfamily,
and B and T cell receptors.
TLRs detect pathogen-associated
molecules and induce pro-inflammatory
proteins and co-stimulatory molecules
that trigger innate and adaptive
immunity (O’Neill, 2004). TLRs
employ many of the same signalling
components as the IL-1 and IL-18
receptors (Martin and Wesche, 2002).
These receptors share a conserved
Toll/IL-1R (TIR) domain and form
dimeric receptor complexes with the
same or different TIR-domain-
containing proteins. These complexes
also recruit intracellular TIR-domain-
containing adapter proteins. Four such
adapter proteins have been well
characterised: Myd88, Mal/TIRAP,
TRIF/TICAM-1 and TRAM/TICAM-2
(O’Neill et al., 2003). With the
exception of TLR3, Myd88 is
universally recruited to all the above
receptor complexes (Janssens and
Beyaert, 2002). The use of the other
adapters is more restricted to specific
TLR members. These adapters recruit
and activate members of the  IRAK
family (Martin and Wesche, 2002).
IRAK-1 is initially recruited to Myd88
in association with Toll-interacting
protein (Tollip). The IRAK-Myd88
association triggers
hyperphosphorylation of IRAK by itself
and/or by other additional kinases,
probably IRAK-4, leading to its
dissociation from Myd88 and Tollip and
its interaction with the downstream
adaptor TRAF-6. The interaction of
IRAK with TRAF-6 leads to activation
of TAK1 (Ninomiya-Tsuji et al., 1999).
IRAK is essential in this activation
process, because it promotes the
translocation of TAK1-binding protein
2 (TAB2) from the membrane to the
cytosol, where TAB2 interacts with
TRAF-6 and bridges the association of
TRAF-6 with TAK1. The latter, with the
help of TAB1, becomes activated and in
turn activates the IKK complex. The
activation of TAK1 by TRAF-6 depends
on the nonclassical polyubiquitinylation
(ubiquitin chains linked through Lys63
of ubiquitin) of TRAF-6 (Deng et al.,
2000; Wang et al., 2001). Interestingly
the tumour suppressor CYLD is a
deubiquitinylating enzyme that inhibits
ubiquitinylation of TRAF proteins and
activation of NF-B (Brummelkamp et
al., 2003; Kovalenko et al., 2003;
Trompouki et al., 2003). CYLD is
mutated in familial cylindromatosis; this
results in loss of its deubiquitinylating
activity, increased TRAF-mediated
activation of NF-B and tumorigenesis.
TRAF-6 can activate other MAP3Ks that
stimulate the IKK complex. It associates
with a novel adaptor protein, ECSIT,
that sequentially activates MEKK-1 and
IKKs (Kopp et al., 1999). Furthermore,
TRAF-6 interacts with MEKK3 and the
latter is essential for activation of IKKs
by TLR4 and IL-1R (Huang et al., 2004).
Finally, TRAF-6 interacts with another
adapter, p62, and activates PKC,
leading to phosphorylation of p65 (see
below) (Sanz et al., 2000).
Nod1 and Nod2 are cytoplasmic
receptors for microbial ligands that can
trigger activation of NF-B (Athman
and Philpott, 2004; Philpott and
Girardin, 2004). Both Nod proteins
recognise peptidoglycan breakdown
products (Athman and Philpott, 2004).
Nod1 acts as a receptor for a tripeptide
motif containing diaminopimelic acid
(DAP) as its terminal amino acid
whereas Nod2 recognises a muramyl
dipeptide (MDP). The activation of the
Nod proteins leads to their
oligomerisation and subsequent
interaction with and activation of
receptor-interacting protein (RIP) 2 (also
known as CARDIAK and RICK). RIP2
then associates with IKK, leading to
activation of the catalytic subunits IKK
and IKK.
The TNF receptor superfamily
represents another collection of
receptors that activate NF-B (Dempsey
et al., 2003; Gaur and Aggarwal, 2003).
Some members, including TNFR1, Fas,
TRAILR-1 and TRAILR-2, contain a
death domain (DD) in their cytoplasmic
regions, whereas others, such as TNFR2,
lymphotoxin (LT)-R and CD40 lack a
DD. However, both receptor types can
activate NF-B (Dempsey et al., 2003).
The engagement of TNFR1, for
example, by TNF leads to the
recruitment of TNF-receptor-associated
death domain (TRADD). TRADD then
associates with TRAF2 and RIP. TRAF-
2 subsequently recruits the IKK complex
to the TNFR-1 complex, where RIP
activates the catalytic IKK subunits via
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MEKK3 (Yang et al., 2001). Members
of the TNF receptor superfamily that
lack a DD contain TRAF-interacting
motifs in their cytoplasmic regions
(Dempsey et al., 2003). Such receptors
directly recruit TRAF proteins and
activate NF-B as described above.
However, these receptors can also
activate NF-B by a non-classical
pathway that is independent of the
degradation of IB.
As stated above, the precursor proteins
p105 and p100 have IB domains in
their C-terminal regions. Whereas the
processing of p105 to p50 is
predominantly constitutive (with IKK-
dependent phosphorylation of p105
tending to promote its complete
degradation), the processing of p100 to
p52 is tightly regulated and signal
dependent (Beinke and Ley, 2004). The
precursor p100 is normally found as a
complex with RelB, and the C-terminal
region of p100 represses RelB-mediated
transcriptional activity (Solan et al.,
2002). The processing of p100 and
release of RelB-p52 is triggered by at
least three members of the TNF receptor
superfamily, namely CD40, LTR and
B-cell-activating-factor receptor (BAFF-
R) (Yamamoto and Gaynor, 2004).
These receptors cause the sequential
activation of NF-B-inducing kinase
(NIK) and IKK (Xiao et al., 2001). The
latter phosphorylates p100, resulting in
its polyubiquitinylation and processing
to p52 (Senftleben et al., 2001). This
allows nuclear translocation of RelB-p52
dimers, which induce genes that are
essential for B-cell development and
lymphoid organogenesis. IKK is the
specific catalytic subunit of the IKK
complex that mediates this non-classical
activation of NF-B. Interestingly,
IKK has an additional nuclear role in
that it catalyses the phosphorylation of
histone H3 at NF-B-regulated
promoters (Anest et al., 2003;
Yamamoto et al., 2003). Such
phosphorylation is a necessary pre-
requisite for CBP-mediated acetylation
of H3 and subsequent enhancement of
transcription.
The sensing of antigens by specific T-
cell receptors (TCRs) and B-cell
receptors (BCRs) on T and B
lymphocytes also leads to activation of
NF-B. The engagement of TCRs leads
to the immediate activation of a number
of protein tyrosine kinases and formation
of very large multi-component receptor
complexes (Weil and Israel, 2004). This
leads to activation of PKC and its
association with Akt, a kinase activated
by the co-stimulatory CD28 pathway
(Schmitz et al., 2003). Although the
immediate substrates for PKC are
unknown, a number of downstream
effectors leading to NF-B have been
identified. Carma 1 (caspase-
recruitment-domain-containing
membrane-associated guanylate kinase)
links PKC to Bcl10, a protein first
identified through analysis of
chromosomal translocations in mucosa-
associated lymphoid tissue (MALT)
lymphomas (Bunnell, 2002). Bcl10 is
phosphorylated by RIP2 and interacts
with a caspase-related protein termed
MALT1. This interaction leads to
recruitment and synergistic stimulation
of the IKK complex. The activation
appears to depend on the non-classical
polyubiquitinylation of IKK that is
induced by Bcl10 in a MALT1- and
Ubc13-dependent manner. This happens
as part of a supermolecular membrane
complex at the contact site between the
T cell and antigen-presenting cell.
Recently 3-phosphoinositide-dependent
kinase 1 (PDK1) has been shown to have
a key role in assembling this complex of
proteins, co-ordinating the recruitment
of both the PKC and MALT1
complexes (Lee et al., 2005). The
activation of NF-B by BCR receptors
shows some similarities to TCR
signalling (Weil and Israel, 2004). 
The engagement of BCRs leads to a
torrent of tyrosine kinase activity and
eventual activation of a PKC isoform
termed PKC that promotes activation
of NF-B. Although the Carma1/
Bcl10/MALT1 is known to play a key
role in activating NF-B in B cells, it is
unclear whether these proteins
functionally link PKC to the IKK
complex.
The regulation of the transactivation of
NF-B represents another level of
control for this transcription factor. Most
work has focused on p65 and the
mapping of its multiple phosphorylation
sites (Schmitz et al., 2004). Thus, Ser276
is phosphorylated by protein kinase A in
response to LPS and by mitogen- and
stress-activated protein kinase 1 (MSK1)
in response to TNF. PKC
phosphorylates Ser311 in response to
TNF. Ser529 is phosphorylated by
casein kinase II (CKII) and the IKK
complex. Finally, Ser536 is
phosphorylated by the catalytic subunits
of IKK and the IKK-related kinases
IKK and TRAF-family-member-
associated (TANK)-binding kinase 1
(TBK1). Other phosphorylation sites
include Ser468 and Thr505 but the
responsible kinase(s) awaits
identification. The phosphorylation of
many of these sites is associated with an
increase in the transcriptional activity of
p65, and is accompanied by enhanced
binding of p65 to coactivating acetylases
such as CBP/p300. Interestingly, the
latter can acetylate p65 at multiple lysine
residues and this is associated with
increased transactivation (Chen and
Greene, 2003). By contrast, histone
deacetylases (HDACs), such as HDAC-
1, HDAC-2 and HDAC-3, deacetylate
p65, leading to repression of
transactivation and also termination of
NF-B activation by increasing the
affinity of NF-B for IB.
In summary, NF-B acts at the
crossroads of many signalling pathways.
Inappropriate or excessive activation of
NF-B can lead to inflammatory
diseases and cancers. The continuing
efforts to increase our molecular
appreciation of the regulation of NF-B
will be of great value in learning to fully
exploit this transcription factor as a
therapeutic target.
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